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Comment on: ‘Trends in the lifetime risk of developing cancer in great Britain: comparison of risk for
those born from 1930 to 1960’—cancer predictions need more context
JL Oke*,1, BD Nicholson1 and B Shinkins1
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford OX2 6GG, UK
Sir,
Projections of lifetime risk and cancer incidence for the next 25 years
reported by Ahmad et al (2015) are alarming but probably realistic. In the last
30 years, the incidence of all cancers in the United Kingdom has risen from
293 cases per 100 000 persons in 1975 to 396 per 100 000 in 2011 (Cancer
Research UK, 2012), a rise of 35%. We were, however, surprised to such
limited discussion or analysis of cancer mortality trends over the equivalent
time period, which has fallen 21% since 1971 (Cancer Research UK, 2012).
There has been a steady and linear increase over time in cancer incidence
(Figure 1, solid black line). Extrapolating this trend forward (black dotted line)
using simple linear regression produces incidence rates that generate lifetime
and cumulative risks that are broadly in line with Ahmad et al’s more
sophisticated approach. Using the same method to extrapolate the trend in all-
cancer mortality (solid grey line) suggests that all-cancer mortality will
continue to decline (grey dashed line). In short, extrapolating current trends
forward sends incidence and mortality in different directions, and this
suggests a future in which cancer becomes more common but at the same time
more benign.
One explanation for detecting increasing levels of cancer on the scale
suggested by Ahmad et al without a concomitant increase in mortality is the
detection of disease that will not go on to cause symptoms or death:
‘overdiagnosis’ (Welch and Black, 2010). This was acknowledged as
contributory to the increased incidence in prostate cancer in relation to
PSA testing, yet similar trends can be seen for thyroid, kidney, melanoma
and breast cancer. Although it is methodologically challenging to take into
account the impact of over-diagnosis and its underlying causes, diagnostic
drift, increasing test sensitivity and changing competing mortality risks,
these are important considerations to note when interpreting incidence data
(Carter et al, 2015).
We call on the authors to publish their projected mortality rates to provide
greater context to these worrying figures. The public deserve clear information
about the drivers behind them, especially given the cumulative risk of over-
diagnosis in an ageing population.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Ahmad AS, Ormiston-Smith N, Sasieni PD (2015) Trends in the lifetime risk of
developing cancer in Great Britain: comparison of risk for those born from
1930 to 1960. Br J Cancer 112: 943–947.
Cancer Research UK (2012) Cancer incidence for all cancers combined. Available
from http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/
all-cancers-combined/#UK (accessed on 13 February 2015).
Cancer Research UK (2012) Cancer mortality for all cancers combined. Available
from http://www.cancerresearchuk.org/cancer-info/cancerstats/mortality/
all-cancers-combined (accessed on 13 February 2015).
Carter JL, Coletti RJ, Harris RP (2015) Quantifying and monitoring overdiagnosis
in cancer screening: a systematic review of methods. BMJ 350: g7773.
Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102(9):
605–613.
500
400
300
200
100
 0
1975 1985 1995 2005 2015 2025 2035
Year of diagnosis (incidence)
or death (mortality)
Pe
r 
10
0 
00
0 
pe
op
le
Incidence
Mortality
Figure 1. All-cancer incidence and mortality in the United Kingdom
from 1975 to 2011(solid lines) and projected incidence and mortality
(dashed lines).
Comment on ‘Dexamethasone exerts profound immunologic interference on treatment efficacy for
recurrent glioblastoma’
Susannah Ellsworth*,1 and Stuart A Grossman2
1Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA and 2Department of Oncology, Medicine, &
Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Sir,
In this manuscript, Dr Wong and colleagues observed that patients with
recurrent glioblastoma who underwent therapy with tumor treating
alternating electrical fields and were on higher doses of dexamethasone
had lower T-lymphocyte counts and shorter survival (Wong et al, 2015). The
investigators attributed these outcomes entirely to ‘global immunosuppres-
sion by dexamethasone’. In fact, this patient population receives three
therapies that are highly toxic to lymphocytes – glucocorticoids, radiation,
and temozolomide. Recent studies have demonstrated that 40% of patients
with newly diagnosed glioblastoma develop grade III and IV lymphopenia
with CD4 counts o200 cells mm 3 2 months after beginning radiation and
temozolomide (Grossman et al, 2011). This profound lymphopenia lasts for
over 1 year and on multivariate analysis is independently associated with
inferior survival. Treatment-induced lymphopenia has also been studied in
other solid tumors that are not treated with dexamethasone or temozolo-
mide; data from these studies strongly point to radiation as the primary
causative factor in treatment-induced lymphopenia. These studies reported
rates of lymphopenia that were very similar to those seen in glioblastoma
and again identified an association between treatment-induced lymphopenia
and survival in patients with pancreatic cancer, non-small cell lung cancer,
and breast cancer. (Balmanoukian et al, 2012; Campian et al, 2013; Wild
et al, 2013; Tang et al, 2014; Afghahi et al, 2015) Two hypotheses have been
advanced to explain this phenomenon. The first relates to the inadvertent
radiation of circulating lymphocytes (MacLennan and Kay, 1978; Yovino
et al, 2013). The second stems from observations that IL-7 levels are
inappropriately low in irradiated patients with severe treatment-related
lymphopenia (Ellsworth et al, 2014). We agree that immune status is an
important prognostic factor in patients with recurrent glioblastoma.
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However, as radiation-associated lymphopenia is common and long-lasting
in patients with glioblastoma, as well as in patients with pancreatic, lung, and
breast cancer, where dexamethasone is not an integral part of therapy, it is
likely that the immunosuppression described by Dr Wong et al was due to
prior radiation exposure, rather than to dexamethasone treatment. At a
minimum, this issue should be formally addressed in this manuscript and in
subsequent work regarding this important topic.
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Response to: Comment on ‘Dexamethasone exerts profound immunologic interference on
treatment efficacy for recurrent glioblastoma’
Eric T Wong*,1 and Kenneth D Swanson1
1Brain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
Sir,
We would like to thank you for an opportunity to respond to the comments
from Drs Ellsworth and Grossman in their letter to the editor concerning
our recent paper, ‘Dexamethasone Exerts Profound Immunologic
Interference on Treatment Efficacy for Recurrent Glioblastoma’, by Wong
et al (2015).
Contrary to the assertion by the authors, our paper did not claim that the
effects of dexamethasone were mediated via steroid-induced lymphopenia. It is
widely accepted that dexamethasone exerts pleotropic effects on the immune
system that lead to the suppression of multiple effector systems required for
therapy-induced tumor rejection (Fauci, 1976; Benedetti et al, 2003). Within our
single institution patient cohort, we aggressively weaned dexamethasone doses
and we found that patient outcome correlated with T-cell counts. T-cell count
was used as a marker of potential immunological competency to test if it
correlated with outcome, as suggested by our initial observation in the phase III
trial that high dexamethasone dose was correlated with a poorer survival. As
pointed out by Drs Ellsworth and Grossman, the observed lymphocyte counts in
our single institution cohort were probably related to patient treatment history,
intrinsic immune state or both, but not necessarily to corticosteroid usage.
Furthermore, overall survival as a function of the effect of dexamethasone in
each of the two arms in the phase III trial was very likely independent of the
T-lymphocyte counts of patients entering the trial, as supported by our single
institution patient cohort where no correlation was observed between
dexamethasone dose and T-lymphocyte count.
The authors also cited their work on the immunosuppressive effect of
radiation and temozolomide when given to patients with newly diagnosed
glioblastomas (Grossman et al, 2011). They found that 40% of patients had
o200 CD4 cellsmm 3 2 months after initiation of treatment and this was
associated with a poorer survival when compared with those withX200 CD4
cellsmm 3. Given that corticosteroid use was not a controlled variable, it is
possible that dexamethasone may have contributed to the poor survival
outcome in this study. Regardless, the overall conclusion of their study was
also consistent with our utilisation of T-lymphocyte counts as a marker of
poor outcome. Furthermore, an earlier study by Hughes et al (2005)
investigated the phenomenon of lymphopenia in the pre-temozolomide
chemo-irradiation era and found that 24% of the cohort had o200 CD4
cellsmm 3 whereas 76% hadX200 CD4 cellsmm 3. Therefore, it is possible
that the addition of temozolomide to dexamethasone plus radiotherapy
increased the proportion of patients who developed poor outcome and
low CD4 lymphocyte count (from 24 to 40%). Taken together, it may be
important to re-examine the potential role of dexamethasone in these two
studies.
Lastly, the authors also cited that treatment-related lymphopenia is a
marker of poor outcome in pancreatic and non-small cell lung cancers
(Balmanoukian et al, 2012; Campian et al, 2013; Tang et al, 2014; Wild et al,
2015). Our data are consistent with this contention, but do not address the
cause of the low T-lymphocyte counts in our patients. It is notable that
patients in these studies also received concurrent emetogenic chemotherapies,
such as taxol/carboplatin, gemcitabine or gemcitabine/carboplatin, and
dexamethasone was likely an important antiemetic in the premedication
regimen and may therefore confound the outcome analysis.
Although it is hard to absolutely devolve the contribution of dexametha-
sone from prior radiation and chemotherapy effects in patients with
recurrent glioblastoma, the NovoTTF-100A monotherapy arm in the phase
III trial nevertheless offered us a unique opportunity to evaluate the sole
effect of dexamethasone dosage because the influence of prior radiation and
chemotherapy was randomized and balanced. In contrast to commonly used
chemotherapeutic regimens (Grossman et al, 2011), NovoTTF-100A does
not exert such deleterious effects on the immune system. Given these
conditions, we were able to determine that subjects who received a
dexamethasone dose of X4.1mg day 1 had a significantly shorter survival
than those who took o4.1mg day 1. Therefore, one of the obvious
implications of our work is that future clinical trials in the glioblastoma
population may need to control for the confounding dexamethasone effect in
outcome. Furthermore, it may be worthwhile to re-examine treatment
outcomes of prior clinical trials based on dexamethasone stratification.
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